Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Stéphanie Légaré, Sherry Lin, Sarah Vahey et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined placebo responses in randomized controlled trials of systemic therapies for cutaneous lupus erythematosus (CLE). Analyzing 33 trials with 2382 placebo-treated participants, the study found a pooled placebo response rate of 42% achieving ≥50% reduction in CLASI-A at the primary endpoint. The findings highlight factors influencing placebo responses, including study start year and follow-up duration.
Key findings
- The pooled proportion of placebo-treated participants achieving ≥50% reduction in CLASI-A was 42%.
- Placebo responses were 21% at Week 8, 33% at Week 24, and 46% at Week 52.
- Higher placebo responses were noted in studies initiated after 2016 and with follow-up durations >24 weeks.
- A positive correlation was found between the proportion of White participants and CLASI-A50 placebo responses.
Why it matters
Understanding placebo responses in clinical trials for CLE is crucial for optimizing trial design and improving the interpretation of efficacy outcomes. This knowledge can help address the unmet medical needs in this patient population.